RNS Number : 8822U
ValiRx PLC
02 March 2026

2 March 2026

ValiRx PLC
("ValiRx" or the "Company")

ValiRx sets up wholly owned Subsidiary ValiRx Animal Health LTD

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health is pleased to announce that it has set up a wholly owned subsidiary ValiRx Animal Health Limited ("**ValiRx Animal Health**").

ValiRx Animal Health has been incorporated to develop and commercialise ValiRx's existing and future oncology assets in the veterinary market. The study of naturally occurring tumours in dogs can inform research into treatments for all types of cancer, including human cancer which often closely resemble each other given that pets share our environment and exposures. Comparative oncology integrates evaluation of therapeutics and biomarkers in veterinary patients with human therapy development and increased interests in advanced treatments for companion animals means there is an opportunity for pets to receive better treatments whilst providing ethical models for human clinical development.

ValiRx Animal Health will benefit from preclinical development work in the Company's human programmes which will then benefit from early clinical read outs to support partnering and human clinical trials. The Board believe that this strategy could lead to earlier commercial opportunities for these assets with Veterinary Pharma partners. Several specialist Veterinary Venture Capital funds have been identified and initial approaches made with the intention that ValiRX Vet will be independently funded.

The Veterinary Oncology market was estimated at $1.58 billion in 2024 and is projected to hit nearly $4.86 billion by 2034 with a CAGR of 12.14% throughout the forecast timeline[1]. The global veterinary oncology market is growing significantly, driven by increasing prevalence of cancer among companion animals, rising pet ownership and advancements in diagnostic imaging and targeted therapies.

[1] 2025 report by Towards Healthcare

Mark Eccleston, CEO of ValiRx commented "*I have spoken previously about our plan to develop our therapeutic portfolio for the benefit of animals as well as humans having previously been involved in the successful development, launch and $28 million sale of a cancer screening test for dogs. So, I am excited that we have now moved forward with plans to set up a dedicated Veterinary subsidiary. There is a strong scientific rationale, as well as market opportunities, for this ethical approach and several examples of companies that have followed this route. As with all our programmes, we have carried out extensive due diligence into the markets and, working with our advisory board, we have identified three key areas - Osteosarcoma, Lymphoma and Hemangiosarcoma.*

"Osteosarcoma in dogs is particularly interesting for complementary development as it closely resembles human paediatric osteosarcoma. Whilst prevalent in dogs, it is a rare but deadly condition in children. Pet patients can therefore generate valuable clinical data to support human translation whilst potential for Orphan Drug Designation in humans offers attractive market exclusivity benefits in rare diseases. Also, given the high unmet need, regulatory approval can be expedited meaning lower investment costs and faster launches. Our CRO, Inaphaea Biolabs has Osteosarcoma PDC models allowing rapid in-vitro screening using our New Approach Methodology. These all align with ValiRx's strategy of smarter development."

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub	https://valirx.com/link/peg6vy
ValiRx plc	**Tel: +44 115 784 0026**

Dr Mark Eccleston, CEO	www.valirx.com Mark.Eccleston@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti	**Tel: +44 (0) 20 7213 0880**
Shard Capital Partners LLP (Sole Broker) Damon Heath	**Tel: +44 (0) 20 7186 9000**
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director	**+44 (0) 115 787 0206** www.vformation.biz lucy@vformation.biz sue@vformation.biz

Subscribe to our news alert service: https://valirx.com/s/f298d1

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUPUPPWUPQGBG